Raising Biotech

As we prepare to launch the first two episodes of Raising Biotech this week, here's a note from creator Surani Fernando on the background behind the podcast and who might find this series valuable. Listen to the trailer which is up now, and follow and subscribe to get notified of new episodes! https://lnkd.in/gU_Qb9HD

Excited to announce another new podcast has joined Health Podcast Network!! I met Surani Fernando earlier this year, and was blown away by the talent and incredible execution of her podcast Raising Biotech. From the simplicity of the shows title, to the expert narration and crafting of the stories in each episode, to the amazing insights and behind-the-scenes perspective, she shares, this podcast is a leading example of how to create audio-first, screen-light content. I highly recommend you add all the episodes to your summer playlist! https://lnkd.in/eGkmxzfW #healthPodNet #biotech #vc #investors

Thrilled to share that Raising Biotech is now part of the Health Podcast Network! 🎉 Big shoutout to Daniel Couchman Kendall for creating such an outstanding community of top-tier, health-focused podcasts. It’s an incredible honor to be invited to join this group! Following the success of our first two seasons (12 episodes), we’re working away on the next chapter. In the meantime, if you missed any episodes, now’s the perfect time to catch up! 🎧 ⏯️ ☕️ While some of the featured companies have since announced exciting news and updates, each episode remains an "evergreen" exploration of the unique origins and journeys of these promising biotechs -- each of which is securing impressive funding to drive ambitious medical breakthroughs. 💰💉💊 Season 1 🎙️: 1. Empress Therapeutics - cracking the code to novel small molecules 2. Ochre Bio - tackling chronic liver disease with human liver models 3. eGenesis, Inc. - breakthroughs with pig kidneys for human transplant 4. Synchron - brain implants allowing thoughts to control a digital device 5. Arialys Therapeutics, Inc. - tackling autoimmune neuropsychiatric diseases 6. Alltrna - leveraging tRNA therapeutics for ultra rare diseases Season 2 🎙️: 1. Mana.bio - programmable delivery of lipid nanoparticles 2. Fauna Bio - applying animal biology to human drug development 3. Ray Therapeutics, Inc. - restoring vision with optogenetics 4. Sparrow Pharmaceuticals, Inc. - solving the 75-year old steroid problem 5. Cerevance - a new approach to treating Parkinson's disease 6. iOmx Therapeutics AG - shaking up the immuno-oncology field ⏯️: Listen to all these episodes on the Health Podcast Network, Apple, Spotify or wherever you listen! https://lnkd.in/eReD-fwt

Congrats to Fauna Bio for being recognized with a Fierce 15 award from Fierce Biotech at such an early stage of R&D! Fauna's episode (S2, E2) on Raising Biotech was super fun to piece together! Take a listen here ⏯️: https://lnkd.in/eHvAz5e5

In the latest episode of Raising Biotech, well known biotech commentator Jared Holz, Healthcare Equity Strategist at Mizuho, gives his outsider's take and first impressions of German cancer biotech iOmx Therapeutics AG. He has seen a lot of companies rise and fall in the immuno-oncology space and speaks more from an investor perspective. During the episode, iOmx's CEO Apollon Papadimitriou discusses the desire for iOmx to IPO in the next two years. Beyond that, they'll see where the road takes them. Jared talks about potential investor appetite and M&A interest for a company like iOmx, pending further data. Give the episode a listen here ⏯ ☕: https://lnkd.in/gu7K-Yfz ...or wherever you get your podcasts! If you liked this episode, please share it around and rate and review it on Apple or Spotify. #biotech #venturecapital #cancer #immunooncology #IPO #investors

We usually hear about how biotech founders go knocking on investor doors for their first fundraising round, with varying success. In iOmx Therapeutics AG's case -- a few poster presentations at a cancer conference saw serious investors approaching them. The company was able to raise €40 million in its initial round (quite large for a European company!). Here's a clip from Raising Biotech's latest episode on the German biotech, with its academic founder Professor Philipp Beckhove from the University of Regensburg. The company has raised €115 million to date (since 2016), has another financing round coming up this year and a desire to go public in the next two years. This will be an interesting company to watch! Give the episode a listen here ⏯️ ☕️: https://lnkd.in/gu7K-Yfz ...or wherever you get your podcasts! If you liked this episode, please share it around and rate and review it on Apple or Spotify. #biotech #venturecapital #immunooncology #cancer #IPO

The final episode of Raising Biotech for season 2 is up! This time we finally dive into the cancer zone with German company iOmx Therapeutics AG. The firm has raised a total of EUR 115 million (Series A and B) since its inception in 2016 and is hoping to take immuno-oncology drug development to new heights. In this episode, CEO Apollon Papadimitriou joins the podcast to speak about iOmx's unique mission with its proprietary iOTarg platform, while scientific founder Professor Phillip Beckhove from the RCI at University of Regensburg, also joins the conversation to take us back to iOmx's origins in the lab and what led his team to produce some groundbreaking research -- tackling tumor immune evasion -- which attracted heavy-hitter investors before the company was born. Apollon gives us updates on ongoing clinical trials, detailed insight into some early and surprising efficacy signals from the Phase I, and plans to initiate proof of concept (PoC) studies in various cancer indications. He also sheds more insight into imminent fundraising plans and potentially pulling the IPO trigger within the next two years. Jared Holz, Healthcare Equity Strategist at Mizuho also joins the podcast to give an outsider's take on iOmx's mission from a unique investor community lens. He discusses current gaps in the market, the potential attractiveness of iOmx pipeline and likely investor appetite should iOmx deliver compelling PoC datasets. A company to watch and worth the listen! Listen (and find time stamps) here ⏯️: Apple: https://lnkd.in/eReD-fwt Spotify: https://lnkd.in/g8n8J_aP This episode is proud to be partnered with Mindgram - a research tool powered by AI serving the global biopharma community. Raising Biotech listeners are able to get an exclusive free trial (link in show notes). MPM BioImpact, Sofinnova Partners, Wellington Partners, M Ventures , ATHOS, MIG Capital #immunooncology #cancer #venturecapital #biotech #IPO

Here's a clip from Raising Biotech's latest episode on Cerevance (Season 2, Episode 5) with expert neurologist Karl Kieburtz from Clintrex and University of Rochester. Karl is one of the most knowledgable KOLs in the field and advises many CNS companies (including Cerevance), so has a deep understanding of the company's NetSseq technology and how its lead Parkinson's asset (CVN 424) differentiates from the current treatment landscape. He also highlights clinical trial challenges the company will need to navigate to yield a successful marketed product. Give the episode a listen here ⏯️☕️: https://lnkd.in/g6sywDj9 ...or wherever you get your podcasts! If you liked this episode, please share it around and rate and review it on Apple or Spotify. #CNS #Parkinsons #neuroscience #biotech #venturecapital #IPO

I recently had the privilege of listening to a Precision Neuroscience panel at #BIO2024 and then stumbled across an insightful episode of the Raising Biotech podcast that also featured Cerevance CEO Craig Thompson, and I've been blown away by their innovative approach to tackling neurodegenerative diseases. My three most exciting takeaways are below: Looking ahead, it’s thrilling to see how Cerevance plans to navigate the challenges and opportunities in the CNS space. What new breakthroughs can we expect from their innovative platform in the next few years? #HealthcareInnovation #Innovation #innovationinpharma #neurodegenerativedisease #ParkinsonsDisease #Biotech #Cerevance

Take a listen to some interesting tidbits from Raising Biotech's latest episode on Cerevance (Season 2, Episode 5). CEO Craig Thompson gives us some extremely tangible nuggets on what the company is planning for its lead Parkinson's asset. In a field full of recent failures and lacklustre drug approvals, the company needs to think proactively about market differentiation as well as pricing. Craig does a great job of explaining this on the podcast -- which will be super helpful to anyone closely following Parkinson's R&D and also investors as Cerevance is looking to soon pull the trigger on IPO. Give the episode a listen here ⏯️☕️: https://lnkd.in/g6sywDj9 ...or wherever you get your podcasts! If you liked this episode, please share it around and rate and review it on Apple or Spotify. #CNS #Parksinsons #biotech #venturecapital #IPO